WuXi Biologics (Cayman)
(OTC) WXIBF
WuXi Biologics (Cayman) Financials at a Glance
Market Cap
$19.45B
Revenue (TTM)
$40.27B
Net Income (TTM)
$8.22B
EPS (TTM)
$0.16
P/E Ratio
28.09
Dividend
$0.00
Beta (Volatility)
0.43 (Low)
Dividend
$0.00
Beta (Volatility)
0.43 (Low)
Price
$4.70
Volume
262
Open
$4.70
Price
$4.70
Volume
262
Open
$4.70
Previous Close
$4.70
Daily Range
$4.70 - $4.70
52-Week Range
$2.85 - $5.61
Dividend
$0.00
Beta (Volatility)
0.43 (Low)
Price
$4.70
Volume
262
Open
$4.70
Previous Close
$4.70
Daily Range
$4.70 - $4.70
52-Week Range
$2.85 - $5.61
WXIBF News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout WuXi Biologics (Cayman)
Industry
Life Sciences Tools and Services
Sector
Health CareEmployees
13,252
CEO
Zhi Sheng Chen, PhD
Website
www.wuxibiologics.comHeadquarters
Wuxi, 214092, CN
WXIBF Financials
Key Financial Metrics (TTM)
Gross Margin
46%
Operating Margin
30%
Net Income Margin
23%
Return on Equity
11%
Return on Capital
12%
Return on Assets
8%
Earnings Yield
3.56%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$19.45B
Shares Outstanding
4.14B
Volume
262
Avg. Volume
10.09K
Financials (TTM)
Gross Profit
$9.76B
Operating Income
$6.47B
EBITDA
$8.17B
Operating Cash Flow
$6.39B
Capital Expenditure
$3.59B
Free Cash Flow
$2.80B
Cash & ST Invst.
$15.75B
Total Debt
$3.11B
WuXi Biologics (Cayman) Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$11.64B
+36.3%
Gross Profit
$5.67B
+73.5%
Gross Margin
48.71%
N/A
Market Cap
$19.45B
N/A
Market Cap/Employee
$1.55M
N/A
Employees
12,575
N/A
Net Income
$2.53B
+123.0%
EBITDA
$4.73B
+122.2%
Quarterly Fundamentals
Net Cash
$12.64B
+89.2%
Accounts Receivable
$8.90B
+43.9%
Inventory
$1.44B
-18.4%
Long Term Debt
$1.85B
-51.7%
Short Term Debt
$1.26B
+71.8%
Return on Assets
7.64%
N/A
Return on Invested Capital
11.88%
N/A
Free Cash Flow
$2.79B
+1176.6%
Operating Cash Flow
$4.60B
+97.1%